Table 6.
Outcomes after SIT
| Characteristics | Failed steroid tapering after SIT | IMC recurrence | ||
|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |
| ICI type | ||||
| Anti-PD-1/L1 monotherapy | Reference | Reference | ||
| Anti-CTLA-4 therapy | 0.50 (0.19–1.29) | 0.150 | 1.09 (0.36–3.37) | 0.871 |
| Colitis grade | ||||
| 1–2 | Reference | Reference | ||
| 3–4 | 4.09 (1.53–10.98) | 0.005 | 1.79 (0.59–3.38) | 0.299 |
| Multiple hospitalizations | 9.05 (2.79–29.33) | < 0.001 | 26.25 (3.22–213.82) | 0.002 |
| Failed steroid tapering before SIT | 3.75 (1.39–10.16) | 0.009 | 2.42 (0.75–7.77) | 0.138 |
| Failed steroid tapering after SIT | – | – | 4.07 (1.29–12.88) | 0.017 |
| Type of SIT | ||||
| Vedolizumab | Reference | Reference | ||
| Infliximab | 0.47 (0.18–1.22) | 0.120 | 12.57 (1.57–100.57) | 0.017 |
| No. of SIT infusions | ||||
| 1–2 | Reference | Reference | ||
| ≥3 | 2.97 (1.13–7.79) | 0.027 | 0.09 (0.01–0.72) | 0.023 |
| Endoscopic remission | 1.68 (0.41–6.96) | 0.474 | 0.15 (0.03–0.79) | 0.025 |
| Histologic remission | 0.67 (0.18–2.46) | 0.543 | 0.18 (0.04–0.88) | 0.033 |
| Number of steroids tapering attempts | 9.50 (3.76–24.01) | < 0.001 | 3.35 (1.68–6.69) | 0.001 |
| Duration from IMC onset to SIT | 1.05 (1.01–1.09) | 0.011 | 1.00 (0.98–1.03) | 0.774 |
| Overall duration of steroids | 1.02 (1.01–1.04) | 0.001 | 1.01 (1.00–1.03) | 0.022 |
| Calprotectin at time of onset | 1.00 (0.99–1.00) | 0.599 | 1.00 (0.99–1.01) | 0.346 |
| Calprotectin after SIT | 1.00 (0.99–1.00) | 0.573 | 1.01 (1.00–1.01) | 0.014 |
| Duration of hospitalization | 1.12 (1.04–1.21) | 0.004 | 1.14 (1.05–1.23) | 0.001 |
| Duration of symptoms | 1.06 (1.03–1.08) | < 0.001 | 1.02 (1.01–1.03) | 0.008 |
Abbreviations: CI, confidence interval; CTLA, cytotoxic T lymphocyte associated protein; SIT, selective immunosuppressive therapy; OR, odds ratio; PD-1, programmed death protein 1; PD-L1, PD-1 ligand